Although metformin is considered to target cancer stem cells in its treatment [168], a recent study indicates that metformin suppresses EOC progression by inactivating stromal fibroblast stimulated by interleukin-6 (IL-6) [169], which cause fibrosis through chronic inflammation in acute peritoneal inflammation models [169]. Here, IL6 is linked to cancer.